📣 VC round data is live. Check it out!

Editas Medicine Valuation Multiples

Discover revenue and EBITDA valuation multiples for Editas Medicine and similar public comparables like NervGen Pharma, Hansa Biopharma, S Biomedics, Eledon Pharmaceuticals and more.

Editas Medicine Overview

About Editas Medicine

Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.


Founded

2013

HQ

United States

Employees

246

Financials (LTM)

Revenue: $35M
EBITDA: ($141M)

EV

$166M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Editas Medicine Financials

Editas Medicine reported last 12-month revenue of $35M and negative EBITDA of ($141M).

In the same LTM period, Editas Medicine generated $35M in gross profit, ($141M) in EBITDA losses, and had net loss of ($144M).

Revenue (LTM)


Editas Medicine P&L

In the most recent fiscal year, Editas Medicine reported revenue of $41M and EBITDA of ($149M).

Editas Medicine is unprofitable as of last fiscal year, with EBITDA margin of (367%) and net margin of (395%).

See analyst estimates for Editas Medicine
LTMLast FY202320242025202620272028
Revenue$35M$41M$78M$32M$41M
Gross Profit$35M————
Gross Margin100%————
EBITDA($141M)($149M)($163M)($233M)($149M)
EBITDA Margin(402%)(367%)(209%)(721%)(367%)
EBIT Margin(414%)(245%)(217%)(739%)(245%)
Net Profit($144M)($160M)($153M)($237M)($160M)
Net Margin(410%)(395%)(196%)(734%)(395%)

Financial data powered by Morningstar, Inc.

Editas Medicine Stock Performance

Editas Medicine has current market cap of $295M, and enterprise value of $166M.

Market Cap Evolution


Editas Medicine's stock price is $3.01.

Editas Medicine share price increased by 0.7% in the last 30 days, and by 75.0% in the last year.

Editas Medicine has an EPS (earnings per share) of $-1.63.

See more trading valuation data for Editas Medicine
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$166M$295M3.8%0.7%36.8%75.0%$-1.63

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Editas Medicine Valuation Multiples

Editas Medicine trades at 4.7x EV/Revenue multiple, and (1.2x) EV/EBITDA.

See NTM and 2027E valuation multiples for Editas Medicine

EV / Revenue (LTM)


Editas Medicine Financial Valuation Multiples

As of May 5, 2026, Editas Medicine has market cap of $295M and EV of $166M.

Editas Medicine has a P/E ratio of (2.1x).

LTMLast FY202320242025202620272028
EV/Revenue4.7x4.1x2.1x5.1x4.1x
EV/EBITDA(1.2x)(1.1x)(1.0x)(0.7x)(1.1x)
EV/EBIT(1.1x)(1.7x)(1.0x)(0.7x)(1.7x)
EV/Gross Profit4.7x————
P/E(2.1x)(1.8x)(1.9x)(1.2x)(1.8x)
EV/FCF(1.0x)(1.0x)(1.2x)(0.8x)(1.0x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Editas Medicine Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Editas Medicine Margins & Growth Rates

In the most recent fiscal year, Editas Medicine reported EBITDA margin of (367%) and net margin of (395%).

See estimated margins and future growth rates for Editas Medicine

Editas Medicine Margins

Last FY20242025202720282029
EBITDA Margin(367%)(721%)(367%)
EBIT Margin(245%)(739%)(245%)
Net Margin(395%)(734%)(395%)
FCF Margin(409%)(678%)(409%)

Editas Medicine Growth Rates

23/2424/2526/2727/2828/29
Revenue Growth(59%)25%
EBITDA Growth43%(36%)
EBIT Growth41%(58%)
Net Profit Growth55%(32%)
FCF Growth60%(24%)

Data powered by FactSet, Inc. and Morningstar, Inc.

Editas Medicine Operational KPIs

Editas Medicine's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.6M for the same period.

Access forward-looking KPIs for Editas Medicine
LTMLast FY202320242025202620272028
Rule of 40(431%)————
Bessemer Rule of X(474%)————
Revenue per Employee—$0.2M———
Opex per Employee—$0.6M———
G&A Expenses to Revenue141%123%89%223%123%
R&D Expenses to Revenue258%222%227%617%222%
Opex to Revenue—345%317%839%345%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Editas Medicine Competitors

Editas Medicine competitors include NervGen Pharma, Hansa Biopharma, S Biomedics, Eledon Pharmaceuticals, LENZ Therapeutics, Amarin Corp, Protara Therapeutics, Lavipharm, Greenwich LifeSciences and Vicore Pharma Holding.

Most Editas Medicine public comparables operate across Biopharmaceuticals, BioTech and DeepTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
NervGen Pharma——(15.1x)(13.2x)
Hansa Biopharma13.8x13.2x(8.6x)(6.3x)
S Biomedics25.9x—(129.5x)—
Eledon Pharmaceuticals——(1.9x)—
LENZ Therapeutics(0.0x)(0.0x)0.0x0.0x
Amarin Corp(0.0x)(0.0x)0.1x0.1x
Protara Therapeutics——(2.3x)(2.1x)
Lavipharm5.4x—27.9x—

This data is available for Pro users. Sign up to see all Editas Medicine competitors and their valuation data.

Start Free Trial

Editas Medicine Funding History

Before going public, Editas Medicine raised $210M in total equity funding, across 3 rounds.


Editas Medicine Funding Rounds

DateStageRaised FromRaisedValuationRev. MultipleDeal Summary
Aug-15Series BBoris Nikolic$120M—Editas Medicine, a Cambridge-based genome-editing startup founded in 2013, raised $120 million in an oversubscribed Series B financing round announced on August 10, 2015, led by Boris Nikolic through his investment vehicle bng0, with participation from high-profile investors including Bill Gates, Deerfield Management, Viking Global Investors, Fidelity Management & Research, T. Rowe Price Associates, Google Ventures, Khosla Ventures, and others. This round nearly tripled the company's prior $43 million funding from Flagship Ventures, Polaris Partners, Third Rock Ventures, and Partners Innovation Fund, providing resources to advance its CRISPR-Cas9 platform for developing treatments targeting cancer, retinal diseases like LCA10 causing blindness, and sickle-cell anemia. CEO Katrine Bosley emphasized a measured approach, noting the company had not yet initiated human T-cell editing programs and aimed to build clinical readiness over the next two years. The investment underscored strong industry confidence in Editas as a pioneer in applying CRISPR-Cas9, a revolutionary gene-editing technology enabling precise DNA modifications, to cure genetic diseases previously untreatable. Backers viewed the funding as positioning Editas for potential IPO and rapid progression to human trials, with Nikolic highlighting the company's forefront role in this scientific frontier. Editas focused on therapeutic applications avoiding controversial uses like embryo editing, prioritizing monogenic diseases with clear genetic targets. The round supported platform maturation and program advancement toward clinic entry, reflecting biotech's growing bet on gene editing amid ethical debates and breakthroughs like the first human T-cell edits.
May-15Undisclosed stageJuno Therapeutics$47M—In May 2015, Juno Therapeutics and Editas Medicine announced an exclusive collaboration and license agreement to develop chimeric antigen receptor (CAR-T) and T cell receptor (TCR) cancer immunotherapies using Editas' CRISPR/Cas9 genome editing technology. Under the terms, Juno agreed to pay Editas $25 million upfront and up to $22 million in research support over five years, with potential milestone payments exceeding $230 million per program plus tiered royalties. Editas Medicine was founded in November 2013 by prominent gene-editing inventors including Feng Zhang, Jennifer Doudna, David Liu, George Church, and J. Keith Joung, with initial Series A funding of $45 million from Flagship Ventures, Polaris Partners, and Third Rock Ventures. The company operated as a discovery-stage genome-editing platform focused on translating CRISPR/Cas9 technology into genomic medicines for cancers, sickle-cell anemia, retinal disease, and Duchenne muscular dystrophy. In August 2015, just three months after the Juno collaboration, Editas raised $120 million in a Series B financing round led by Boris Nikolic's investment vehicle bng0, with participation from Bill Gates and investors including Deerfield Management, Viking Global Investors, and Fidelity Management & Research.
Nov-13Series AFlagship Pioneering; Partners Innovation Fund; Polaris Partners; Third Rock Ventures$43M—Editas Medicine was founded in 2013 as a transformative genome editing company focused on developing therapeutics using CRISPR/Cas9 and TALEN technologies. The company was established by world-leading scientists including Feng Zhang from MIT, George Church and David Liu from Harvard, Keith Joung from Harvard, and Jennifer Doudna from UC Berkeley, positioned to translate cutting-edge genome editing discoveries into life-changing medicines for patients with genetic diseases. In November 2013, Editas secured a $43 million Series A financing round led by Flagship Ventures, Polaris Partners, and Third Rock Ventures, with participation from Partners Innovation Fund established by Massachusetts General Hospital and Brigham and Women's Hospital. Kevin Bitterman, principal at Polaris Partners, joined as interim president. The company's strategy focused on rare inherited diseases, with particular emphasis on ophthalmologic conditions; its most advanced program was Leber Congenital Amaurosis type 10 (LCA10), a form of progressive blindness, with plans to initiate a proof-of-concept clinical trial by 2017. The company also established a collaboration with Juno Therapeutics to explore CRISPR applications in immuno-oncology. By the time of its February 2016 IPO at $16 per share, Editas had raised an additional $120 million in August 2015 and possessed 20 issued U.S. and European patents with 200 pending applications.

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Editas Medicine

When was Editas Medicine founded?Editas Medicine was founded in 2013.
Where is Editas Medicine headquartered?Editas Medicine is headquartered in United States.
How many employees does Editas Medicine have?As of today, Editas Medicine has over 246 employees.
Who is the CEO of Editas Medicine?Editas Medicine's CEO is Gilmore O’Neill.
Is Editas Medicine publicly listed?Yes, Editas Medicine is a public company listed on Nasdaq.
What is the stock symbol of Editas Medicine?Editas Medicine trades under EDIT ticker.
When did Editas Medicine go public?Editas Medicine went public in 2016.
Who are competitors of Editas Medicine?Editas Medicine main competitors include NervGen Pharma, Hansa Biopharma, S Biomedics, Eledon Pharmaceuticals, LENZ Therapeutics, Amarin Corp, Protara Therapeutics, Lavipharm, Greenwich LifeSciences, Vicore Pharma Holding.
What is the current market cap of Editas Medicine?Editas Medicine's current market cap is $295M.
What is the current revenue of Editas Medicine?Editas Medicine's last 12 months revenue is $35M.
What is the current revenue growth of Editas Medicine?Editas Medicine revenue growth (NTM/LTM) is (29%).
What is the current EV/Revenue multiple of Editas Medicine?Current revenue multiple of Editas Medicine is 4.7x.
Is Editas Medicine profitable?No, Editas Medicine is not profitable.
What is the current EBITDA of Editas Medicine?Editas Medicine has negative EBITDA and is not profitable.
What is Editas Medicine's EBITDA margin?Editas Medicine's last 12 months EBITDA margin is (402%).
What is the current EV/EBITDA multiple of Editas Medicine?Current EBITDA multiple of Editas Medicine is (1.2x).
What is the current FCF of Editas Medicine?Editas Medicine's last 12 months FCF is ($167M).
What is Editas Medicine's FCF margin?Editas Medicine's last 12 months FCF margin is (478%).
What is the current EV/FCF multiple of Editas Medicine?Current FCF multiple of Editas Medicine is (1.0x).
How many companies Editas Medicine has acquired to date?Editas Medicine hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Editas Medicine has invested to date?Editas Medicine hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Editas Medicine

Lists including Editas Medicine

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial